April 14, 2008Clinical Science
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Key result
Apolipoprotein C-III is an emerging cardiovascular risk factor strongly associated with hypertriglyceridaemia and delayed catabolism of triglyceride-rich lipoproteins in the metabolic syndrome.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Metabolic syndrome dyslipidaemia drives CVD risk; leaves open optimal management strategies in insulin-resistant patients.
Key Points
- The aim is to understand the relationship between apolipoprotein C-III and cardiovascular disease risk associated with the metabolic syndrome.
- Reviewed metabolic syndrome and its link to dyslipidaemia and cardiovascular disease risk.
- Analyzed apolipoprotein C-III’s role in lipoprotein metabolism and atherosclerosis development.
- Discussed therapies that target apoC-III modulation in the context of metabolic syndrome.
- Increased apoC-III levels correlated with impaired catabolism of triacylglycerols and triacylglycerol-rich lipoproteins (TRLs).
- ApoC-III demonstrates a direct role in promoting atherosclerosis.
- Potential therapies like PPAR agonists and statins can effectively regulate apoC-III transport.
PICO
P
Population
Metabolic syndrome and cardiovascular disease
E
Exposure / Comparator
Apolipoprotein C-III
Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and cardiovascular disease risk in the metabolic syndrome.
Cite This Study
Ooi et al. (2008) conducted a review in Metabolic syndrome and cardiovascular disease. Apolipoprotein C-III was evaluated. Apolipoprotein C-III is an emerging cardiovascular risk factor strongly associated with hypertriglyceridaemia and delayed catabolism of triglyceride-rich lipoproteins in the metabolic syndrome.